Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Immunotherapy Combinations in PD-L1 High Advanced/Metastatic NSCLC
NCT05565378Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Oct 2022
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 2 trial of belrestotug in non-small cell lung cancer (NSCLC), sponsored by GSK. Started Oct 2022; status: active, not recruiting.
02
Drugs
belrestotug
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05565378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05565378.